Scientists explore CA2 neuron mitochondria for memory loss targets
The team will receive $2 million over five years to investigate the CA2 brain region for the development of neurological therapies.
List view / Grid view
The team will receive $2 million over five years to investigate the CA2 brain region for the development of neurological therapies.
The study showed that DNA “de-methylation” activity can be targeted to anywhere in the DNA and may be a new therapeutic strategy.
Researchers discovered that cardiovascular damage was caused by reduced microRNA-210 levels in patient cells and mice with type 2 diabetes.
The absence of interleukin-36 receptor antagonist (IL-36Ra) significantly slowed down wound healing in ischemia-reperfusion injuries in mice.
The study found that deleting the ABI3 gene in mice increased plaques and inflammation in the brain, suggesting avenues for new treatments.
Scientists discover a long noncoding RNA, termed NXTAR, and a small molecule drug that could be used to treat prostate cancer.
Scientists utilised CRISPR technology and deep learning systems to investigate the genes associated with polycystic kidney disease.
The peptide-centric chimeric antigen receptors killed neuroblastoma cells in mice and could potentially expand the pool of immunotherapeutic targets.
ATH434 reversed some of the gastrointestinal damage to the enteric nervous system associated with Parkinson's disease in a pre-clinical study.
An experimental drug enhanced the benefit of immunotherapy, reducing and in some cases eliminating pancreatic cancer in mice.
The gene therapy restored the ability of neurons to convert levodopa to dopamine and may help develop therapies to slow disease progression.
Moderna and Metagenomi have announced a collaboration to jointly create next-generation in vivo gene editing therapeutics.
Neutralising monoclonal antibodies protected aged macaque monkeys from SARS-CoV-2 and reduced inflammation, including in cerebrospinal fluid, a new study has shown.
Scientists have discovered a novel pathway and enzyme that causes thrombosis in chronic kidney disease (CKD) patients, indicating a new drug target.
Treatment with Viking Therapeutics' dual agonists resulted in mean reductions in body weight of up to 27 percent compared to semaglutide-treated animals.